Universität zu Köln

Krohne, Tim U., Muether, Philipp S., Stratmann, Nina K., Holz, Frank G., Kirchhof, Bernd, Meyer, Carsten H. ORCID: 0000-0002-0530-5298 and Fauser, Sascha (2015). INFLUENCE OF OCULAR VOLUME AND LENS STATUS ON PHARMACOKINETICS AND DURATION OF ACTION OF INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS. Retin.-J. Retin. Vitr. Dis., 35 (1). S. 69 - 75. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1539-2864

Full text not available from this repository.

Abstract

Purpose: To assess the effects of ocular axial length, refraction, and lens status on pharmacokinetics and duration of action of the vascular endothelial growth factor (VEGF) inhibitors ranibizumab and bevacizumab after intravitreal injection in humans. Methods: In 119 eyes of 119 patients, aqueous humor was sampled at different time points after intravitreal injection of ranibizumab or bevacizumab, and either drug or VEGF concentrations were measured by enzyme-linked immunosorbent assays and Luminex multiplex bead technology, respectively. Relative deviation of the measured drug concentrations from the time-corrected mean values was calculated (n = 41). Repetitive VEGF measurements were preformed to identify the duration of complete suppression of ocular VEGF activity for individual eyes (n = 78). In addition, axial length, spherical equivalent refraction, and lens status were determined. Results: For neither ranibizumab nor bevacizumab, a correlation between ocular pharmacokinetics (as measured by relative deviation of drug concentration from the mean) and axial length was detected in phakic eyes (Spearman's correlation coefficient, r = 0.084; P = 0.600). Similarly, the duration of action of intravitreal ranibizumab (as measured by VEGF suppression time) did not correlate with spherical equivalent refraction in phakic eyes (Spearman's correlation coefficient, r = 0.164; P = 0.301) and was not different between phakic and pseudophakic eyes (P = 0.694; Mann-Whitney U test). Conclusion: The results indicate that ocular volume and lens status have no relevant impact on ocular pharmacokinetics and duration of action of VEGF-inhibitory drugs and may, thus, be excluded as factors accounting for the high interindividual variability in morphologic and functional responses to intravitreal anti-VEGF therapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Krohne, Tim U. UNSPECIFIED UNSPECIFIED UNSPECIFIED Muether, Philipp S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Stratmann, Nina K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Holz, Frank G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kirchhof, Bernd UNSPECIFIED UNSPECIFIED UNSPECIFIED Meyer, Carsten H. UNSPECIFIED orcid.org/0000-0002-0530-5298 UNSPECIFIED Fauser, Sascha UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-418053
DOI:	10.1097/IAE.0000000000000265
Journal or Publication Title:	Retin.-J. Retin. Vitr. Dis.
Volume:	35
Number:	1
Page Range:	S. 69 - 75
Date:	2015
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1539-2864
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DIABETIC MACULAR EDEMA; INTRAOCULAR PHARMACOKINETICS; RANIBIZUMAB TREATMENT; VITRECTOMIZED EYES; PSEUDOPHAKIC EYES; BEVACIZUMAB; DEGENERATION; INJECTION; HUMANS Multiple languages Ophthalmology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/41805